Core Viewpoint - A class action lawsuit has been filed against Jayud Global Logistics Limited (NASDAQ: JYD) for allegedly engaging in a fraudulent stock promotion scheme that misled investors [1][2]. Allegations - The complaint alleges that Jayud failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - Jayud's public statements and risk disclosures did not mention the false rumors and artificial trading activity that influenced the stock price [2]. Stock Price Surge - In the weeks leading up to April 2025, Jayud's share price increased from approximately $1.00 to an all-time high of around $8.00 per share, despite a lack of fundamental news to justify this rise [3]. - Investigations revealed that Jayud was involved in a "pump-and-dump" scheme, where impersonators promoted the stock in online forums and social media to create a buying frenzy among retail investors [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by January 20, 2026 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. - Robbins LLP has a history of advocating for shareholder rights and aims to help recover losses and improve corporate governance [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc due to allegations of misleading investors regarding the performance of its North America Fiber Cement segment between May 20 and August 18, 2025 [3]. Group 1: Allegations and Financial Impact - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements and failing to disclose that the company misled investors about the strength of its key segment, despite knowing about inventory destocking by distributors [3]. - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected fiscal 2026 earnings, attributing this to high borrowing costs [3]. - Following the announcement, the price of James Hardie's American Depositary Receipt (ADR) fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased securities in James Hardie between May 20, 2025, and August 18, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of December 23, 2025, to seek the role of lead plaintiff in the class action [1][3]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]. - Faruqi & Faruqi also invites anyone with information regarding James Hardie's conduct, including whistleblowers and former employees, to come forward [5].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly misleading investors regarding the progress and quality of its prostate cancer therapeutic candidates and supply chain [1][2]. Allegations - The lawsuit claims that Telix Pharmaceuticals materially overstated the progress of its prostate cancer therapeutic candidates, TLX591 and TLX592, as well as the quality of its supply chain and partners [2]. - Investors were reportedly caught off guard when Telix disclosed an SEC investigation into its disclosures related to the development of its prostate cancer therapeutic candidates on July 22, 2025 [3]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA, citing deficiencies in chemistry, manufacturing, and controls, and requested additional data to establish comparability of the drug product used in the phase 3 clinical trial [3]. Impact on Stock - Following the announcement of the SEC investigation and the FDA's CRL, the price of Telix's American Depositary Shares (ADSs) declined significantly [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by January 9, 2026, but participation is not required to be eligible for recovery [4]. About Robbins LLP - Robbins LLP is a law firm specializing in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Perrigo Company plc securities, alleging that the company made materially false and misleading statements regarding its infant formula business and financial results during the class period from February 27, 2023, to November 4, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance and required substantial capital and operational expenditures beyond previously stated estimates [5]. - It is alleged that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow [5]. - The lawsuit asserts that the positive statements made by Perrigo regarding its business operations and prospects were materially misleading and lacked a reasonable basis [5]. Group 2: Participation Information - Investors who purchased Perrigo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the court by January 16, 2026, to represent other class members in directing the litigation [1][3].

Core Points - Skye Biosciences is conducting a conference call to discuss the results of its Phase IIa clinical trial [1] - The call includes forward-looking statements regarding the company's development activities and timelines, which are subject to risks and uncertainties [2] - The CEO of Skye Biosciences, Punit Dhillon, is leading the discussion [3]

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2024 were $7.8 million, up from $1.6 million in Q4 2023, primarily due to clinical and manufacturing costs associated with the Phase IIa CBeyond study for nimacimab [30] - For the year ended December 31, 2024, research and development expenses totaled $18.7 million, compared to $5.8 million in 2023, driven by increased clinical costs and employee-related benefits [31] - General and administrative expenses for Q4 2024 were $4.6 million, up from $2.5 million in Q4 2023, mainly due to stock-based compensation and professional services [32] - The net loss for the year ended December 31, 2024, was $26.6 million, a decrease from $37.6 million in 2023, attributed to the expensing of acquisition costs in 2023 [33] Business Line Data and Key Metrics Changes - The company has shifted focus from the development of SBI-100 to nimacimab, reallocating resources to achieve clinical milestones [11] - The CBeyond clinical trial for nimacimab saw over-enrollment, completing enrollment with 136 patients, exceeding the planned 120 patients [9] Market Data and Key Metrics Changes - The company views nimacimab as a differentiated alternative in the obesity treatment market, especially as the GLP-1 receptor agonist space becomes crowded [24] - Recent industry deals highlight the growing interest in non-incretin mechanisms for obesity treatment, validating the potential of CB1 inhibitors like nimacimab [81] Company Strategy and Development Direction - The company plans to engage with regulators for a Phase IIb dose-escalation study anticipated to start in Q2 2026, while also enhancing manufacturing capabilities [22] - The strategic decision to extend the CBeyond trial to 52 weeks aims to gather more comprehensive safety and efficacy data, which will support regulatory discussions [19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in nimacimab's safety profile, noting no neuropsychiatric side effects in the Phase I study and ongoing positive reviews from the Data Safety Monitoring Board [16][50] - The company anticipates that the additional data from the extended trial will enhance understanding of nimacimab's capabilities and support its regulatory package [19] Other Important Information - The company reported cash and cash equivalents of $68.4 million as of December 31, 2024, with an operating cash burn averaging $6.3 million per quarter [34][36] - The company has eliminated related party balances and remediated litigation matters during 2024, improving its financial position [35] Q&A Session Summary Question: What can be expected from the 26 and 52-week readouts? - Management indicated that the extension study was strategic to gather longer-term efficacy and safety data, which is crucial for regulatory discussions [42][43] Question: How does the removal of the interim analysis affect the study's power? - The removal of the interim analysis preserves the study's power, allowing for a more robust efficacy and safety analysis with a larger patient dataset [60][100] Question: What feedback has been received from investigators regarding the study? - Investigators have shown strong enthusiasm for the obesity trials, contributing to the rapid enrollment pace [96] Question: Will there be additional DEXA scans during the extended study? - Yes, there will be a DEXA scan at the midpoint of the extension and another at the end of the treatment period to assess body composition changes [99] Question: How does the company view the potential for nimacimab in diabetic patients? - The company is excited about testing nimacimab in diabetic populations, as its mechanism may improve insulin sensitivity and address inflammation [132]